FDA's Case Against Cheap-Drug Sellers Rests on a Rival CEO Turned Informant
Federal agents charged CANARX treasurer John Thomas Howard with smuggling and importing misbranded drugs, the first criminal case against an alternative funding program. His brother and company president Bob Howard is still wanted. The FDA's break came from a rival CEO who cut a deal and recorded phone calls.
- Original source: cnbc.com.
- The source published it on Nov 18, 2026 at 9:06 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
John Thomas Howard, treasurer and director of the Canadian healthcare company CANARX, was arrested Nov. 8 in the tunnel connecting Detroit and Canada. He faces charges of smuggling, conspiracy and importing a misbranded drug for patient use in the United States. His brother Bob Howard, the company's president, is wanted on similar charges and was still being sought as of last week, according to court records.
The case is the first criminal prosecution by U.S. authorities against a company in the alternative funding program industry, or AFP, which promises to lower or wipe out prescription drug costs by sourcing medications from international markets. The FDA and Department of Homeland Security call that model illegal and a risk to patients, pointing to unregulated foreign-market drugs and possible counterfeits. CANARX, based in Windsor, Ontario, was founded in 2002 and was featured in a CNBC investigation into the AFP boom.
The FDA's break came from a competitor. A 35-page affidavit dated Oct. 29 and unsealed last week, written by FDA Office of Criminal Investigations special agent Dustin Dobbs, traces the case to a tip about ScriptSourcing, a Bonita Springs, Florida, company that marketed its international prescription program to self-funded employer health plans. The FDA had ScriptSourcing on its radar since at least 2022. In August 2025, Dobbs posed as someone interested in the AFP business and emailed the company; an employee replied that ScriptSourcing was FDA-compliant, carried more than 2,000 name-brand specialty medications and worked with over 3,000 self-funded health plans. That same year, the agency learned of two alleged incidents where ScriptSourcing-sourced drugs harmed patients, according to the affidavit: one woman was hospitalized with a small bowel obstruction after using misbranded Mounjaro from a Canadian pharmacy, and another patient was seriously injured by a counterfeit medication.
Facing that scrutiny, ScriptSourcing founder and CEO Gary Becker flipped. By May 2026 he was a cooperating witness against CANARX, telling the FDA he had done drug-importation business with the company and that it handed him a quote-unquote road map for how to operate, according to the affidavit. ScriptSourcing also gave the FDA a spreadsheet of financial transactions with CANARX from 2021 to 2026 showing roughly 16,549 prescription drugs dispensed. In recorded calls between June and July 2026, Becker discussed foreign importations with the Howard brothers. Dobbs wrote that the calls show John Howard knew the import routes from Canada into the U.S. and tried to shape them for CANARX's illegal drug importation program, and that both brothers knew the drugs could not legally enter the country. Among shipments en route or being prepared was a package containing Neupro, an FDA-regulated drug for Parkinson's disease and restless legs syndrome.
Joseph Morris, CANARX's general counsel, told CNBC the Howard brothers deny all charges, will defend vigorously and expect to be vindicated in court. Becker's attorney, George Karavetsos, declined to comment but confirmed Monday that ScriptSourcing is no longer in business. The FDA did not respond to CNBC's request for comment on the affidavit's details.
The AFP model is also the target of a civil lawsuit Gilead Sciences filed in December 2024, alleging several companies including CANARX illegally imported its HIV drug Biktarvy. CANARX has not responded to those allegations. After the charges against the Howard brothers, Gilead told CNBC it welcomed the government's efforts to hold accountable those whose conduct may put patients at risk.
TopicsCANARX · ScriptSourcing · John Thomas Howard · Bob Howard · Gary Becker · FDA · Gilead Sciences · Biktarvy
Source: cnbc.com
Written by AI from verified reporting.
More stories
- Health & science cardiovascularbusiness.com 0 viewsFDA moves to yank liquid statin FloLipid off US shelves
- Health & science x.com 0 viewsAdults Ask About Another Measles Shot as US, Mexico and Bolivia Lose Elimination Status
- Health & science finance.yahoo.com 1 viewIonis' Tryngolza becomes EU's first RNA therapy for severe high triglycerides
- Health & science theguardian.com 0 viewsE coli toxin colibactin flagged to MPs as prime suspect in under-50 bowel cancer rise

